Risk of invasion and axillary lymph node metastasis in ductal carcinoma in situ diagnosed by core-needle biopsy

British Journal of Surgery

Volumn 94, Issue 8, 2007, Pages 952-956

  Meijnen, P ^a   Oldenburg, H S A ^a   Loo, C E ^a   Nieweg, O E ^a   Peterse, J L ^a   Rutgers, E J T ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; DUCTAL CARCINOMA IN SITU; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MAMMOGRAPHY; NEEDLE BIOPSY; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AGED; ANALYSIS OF VARIANCE; AXILLA; BIOPSY, NEEDLE; BREAST; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM INVASIVENESS; RISK FACTORS;

EID: 34547808207     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.5735     Document Type: Article

References (23)

1. Ernster VL, Barclay J, Kerlikowske K, Wilkie H, Ballard-Barbash R. Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology, and end results program. Arch Intern Med 2000; 160: 953-958.
2. Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853 - a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 2006; 24: 3381-3387.
3. Verkooijen HM, Core Biopsy After Radiological Localisation (COBRA) Study Group. Diagnostic accuracy of stereotactic large-core needle biopsy for nonpalpable breast disease: results of a multicenter prospective study with 95% surgical confirmation. Int J Cancer 2002; 99: 853-859.
4. Lee CH, Carter D, Philpotts LE, Couce ME, Horvath LJ, Lange RC et al. Ductal carcinoma in situ diagnosed with stereotactic core needle biopsy: can invasion be predicted? Radiology 2000; 217: 466-470.
5. Jackman RJ, Burbank F, Parker SH, Evans WP III, Lechner MC, Richardson TR et al. Stereotactic breast biopsy of nonpalpable lesions: determinants of ductal carcinoma in situ underestimation rates. Radiology 2001; 218: 497-502.
6. Hoorntje LE, Schipper ME, Peeters PH, Bellot F, Storm RK, Borel Rinkes IH. The finding of invasive cancer after a preoperative diagnosis of ductal carcinoma-in-situ: causes of ductal carcinoma-in-situ underestimates with stereotactic 14-gauge needle biopsy. Ann Surg Oncol 2003; 10: 748-753.
7. Goyal A, Douglas-Jones A, Monypenny I, Sweetland H, Stevens G, Mansel RE. Is there a role of sentinel lymph node biopsy in ductal carcinoma in situ?: analysis of 587 cases. Breast Cancer Res Treat 2006; 98: 311-314.
8. Mittendorf EA, Arciero CA, Gutchell V, Hooke J, Shriver CD. Core biopsy diagnosis of ductal carcinoma in situ: an indication for sentinel lymph node biopsy. Curr Surg 2005; 62: 253-257.
9. Wilkie C, White L, Dupont E, Cantor A, Cox CE. An update of sentinel lymph node mapping in patients with ductal carcinoma in situ. Am J Surg 2005; 190: 563-566.
10. Yen TW, Hunt KK, Ross MI, Mirza NQ, Babiera GV, Meric-Bernstam F et al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg 2005; 200: 516-526.
11. Dillon MF, McDermott EW, Quinn CM, O'Doherty A, O'Higgins N, Hill AD. Predictors of invasive disease in breast cancer when core biopsy demonstrates DCIS only. J Surg Oncol 2006; 93: 559-563.
12. Silverstein MJ, Lagios MD, Recht A, Allred DC, Harms SE, Holland R et al. Image-detected breast cancer: state of the art diagnosis and treatment. J Am Coll Surg 2005; 201: 586-597.
13. Rutgers EJ, Jansen L, Nieweg OE, de Vries J, Schraffordt Koops H, Kroon BB. Technique of sentinel node biopsy in breast cancer. Eur J Surg Oncol 1998; 24: 316-319.
14. Holland R, Peterse JL, Millis RR, Eusebi V, Faverly D, van de Vijver MJ et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 1994; 11: 167-180.
15. Meijnen P, Peterse JL, Oldenburg HS, Woerdeman LA, Rutgers EJ. Changing patterns in diagnosis and treatment of ductal carcinoma in situ of the breast. Eur J Surg Oncol 2005; 31: 833-839.
16. Katz A, Gage I, Evans S, Shaffer M, Fleury T, Smith FP et al. Sentinel lymph node positivity of patients with ductal carcinoma in situ or microinvasive breast cancer. Am J Surg 2006; 191: 761-766.
17. Veronesi P, Intra M, Vento AR, Naninato P, Caldarella P, Paganelli G et al. Sentinel lymph node biopsy for localised ductal carcinoma in situ? Breast 2005; 14: 520-522.
18. Zavagno G, Carcoforo P, Marconato R, Franchini Z, Scalco G, Burelli P et al. Role of axillary sentinel lymph node biopsy in patients with pure ductal carcinoma HI situ of the breast. BMC Cancer 2005; 5: 28.
19. Feldman SM, Krag DN, McNally RK, Moor BB, Weaver DL, Klein P. Limitation in gamma probe localization of the sentinel node in breast cancer patients with large excisional biopsy. J Am Coll Surg 1999; 188: 248-254.
20. Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. N Engl J Med 2004; 350: 1430-1441.
21. Buerger H, Otterbach F, Simon R, Schafer KL, Poremba C, Diallo R et al. Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. J Pathol 1999; 189: 521-526.
22. Warnberg F, Nordgren H, Bergkvist L, Holmberg L. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness. Br J Cancer 2001; 85: 869-874.
23. Dillon MF, Hill AD, Quinn CM, O'Doherty A, McDermott EW, O'Higgins N. The accuracy of ultrasound, stereotactic, and clinical core biopsies in the diagnosis of breast cancer, with an analysis of false-negative cases. Ann Surg 2005; 242: 701-707.